Results 111 to 120 of about 22,482 (226)

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration

, 2013
Michael Thomas,1 Shaymaa S Mousa,2 Shaker A Mousa1 1Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2The Johns Hopkins University, Baltimore, MD, USA Abstract: Wet age-related macular degeneration (AMD)
Thomas M, Mousa SS, Mousa SA
core  

EFFICIENCY OF AFLIBERCEPT IN CLINICAL PRACTICE [PDF]

, 2017
Introduction. Age-related macular degeneration is a leading cause of severe vision loss worldwide, frequently resulting in legal blindness. Implementation of anti-VEGF therapy in clinical practice was an important milestone in the treatment of age ...
A. V. Kulagina
core   +1 more source

Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration

BMJ Open Ophthalmology
Purpose Age-related macular degeneration (AMD) remains the leading cause of blindness in developed countries. There are many different intravitreal anti-vascular endothelial growth factor (VEGF) drugs available for the treatment of neovascular AMD (nAMD).
Siegfried Priglinger, Jakob Siedlecki, Benedikt Schworm, Franziska Eckardt, Michael Hafner, Ben Asani, Caspar Liesenhoff, Alexander Kufner, Johannes Benedikt Schiefelbein   +8 more
doaj   +1 more source

Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema

Journal of Clinical Medicine
Background: To report on the outcome of intravitreal brolucizumab compared to aflibercept in patients with diabetic macular edema (DME). Methods: Prospective, observational, study in 35 eyes of 24 patients with a loading dose of five injections of 6 mg ...
Anne Rübsam, Leopold Hössl, Saskia Rau, A. Böker, Oliver Zeitz, Antonia M. Joussen   +5 more
semanticscholar   +1 more source

Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

, 2015
Stephane A Régnier,1 William Malcolm,2 Jennifer Haig,3 Weiguang Xue41Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals UK Ltd, Frimley Business Park, UK; 3Optum, Burlington, ON, Canada; 4Optum, Uxbridge, UKBackground: Ranibizumab ...
Xue W, Haig J, Régnier SA, Malcolm W   +3 more
core  

Current role of aflibercept in retinopathy of prematurity – A review

Indian Journal of Ophthalmology
The introduction of intravitreal anti-vascular endothelial growth factor (VEGF) therapy has transformed the management of severe retinopathy of prematurity (ROP) in the zone I/zone II posterior region and aggressive ROP by enabling rapid disease ...
Devesh Kumawat, Nawazish Shaikh, Parijat Chandra   +2 more
doaj   +1 more source

Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an OHDSI Network Study

Ophthalmology Retina
Objective or Purpose: A) To characterize the incidence of kidney failure associated with intravitreal anti-vascular endothelial growth factor (VEGF) exposure, and B) compare the risk of kidney failure in patients treated with ranibizumab, aflibercept, or
Cai Cindy, Akihiko Nishimura, M. Bowring, Erik Westlund, Diep Tran, J. H. Ng, Paul Nagy, Michael Cook, Jody-Ann McLeggon, Scott L. DuVall, M. Matheny, A. Golozar, A. Ostropolets, Evan P. Minty, Priya Desai, F. Bu, Brian C. Toy, Michelle Hribar, T. Falconer, Linying Zhang, Laurence Lawrence-Archer, Michael V. Boland, Kerry E. Goetz, Nathan Hall, A. Shoaibi, Jenna M. Reps, A. Sena, C. Blacketer, J. Swerdel, K. Jhaveri, Edward Lee, Zachary D. Gilbert, S. Zeger, Deidra C. Crews, M. Suchard, G. Hripcsak, Patrick B. Ryan   +36 more
semanticscholar   +1 more source

Effect of intravitreal aflibercept on corneal endothelial cells: a 6-month follow-up study

, 2019
Tetsuya Muto, Shigeki Machida Department of Ophthalmology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan Purpose: To determine the effect of intravitreal aflibercept injection on the corneal endothelium in patients with diabetic or
Muto T, Machida S
core  

Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study

International Journal of Retina and Vitreous
To evaluate the structural and functional changes in eyes with neovascular age related macular degeneration (nAMD) in a real-world setting, using Treat and Extend protocol (T&E), comparing four antiangiogenic agents.
T. Kanadani, N. Rabelo, D. Takahashi, Lucas M. Magalhães, M. Farah   +4 more
semanticscholar   +1 more source

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration

, 2015
Chandrakumar Balaratnasingam,1–3 Elona Dhrami-Gavazi,1,2,4 Jesse T McCann,1,2,4,5 Quraish Ghadiali,1,2 K Bailey Freund1,2,4,5 1Vitreous-Retina-Macula Consultants of New York, NY, USA; 2LuEsther T Mertz Retinal Research Center, Manhattan Eye, Ear ...
Freund KB, Balaratnasingam C, McCann JT, Ghadiali Q, Dhrami-Gavazi E   +4 more
core